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Abstract 
 Survivin, the smallest member of the Inhibitor of Apoptosis Protein (IAP) family, is over-
expressed in cells of almost all cancers but not most adult normal tissues. Survivin expression is 
required for cancer cell survival and knocking down its expression or inhibiting its function using 
molecular approaches all cause spontaneous apoptosis. Thus, survivin is an attractive and perhaps 
an ideal target for cancer drug discovery. However, an FDA-approved drug targeting survivin has 
yet to emerge. In this review, we examine and evaluate various strategies that have been tested in 
targeting survivin and the stages of each survivin inhibitor to help understand why we have not yet 
been successful. We also provide future perspectives moving forward in targeting survivin for drug 
discovery. 
 
Teaser 
 This review provides a comprehensive analysis of drug discovery targeting survivin and 
evaluate the advantages/disadvantages of survivin inhibitor as well as insights on moving forward 
in targeting survivin for drug discovery.  
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Introduction 
 Resistance to traditional chemotherapy and new targeted therapies is a classical hallmark of 
many cancers and remains a pressing challenge to a successful clinical outcome for a significant 
population of cancer patients [1].  The need for new specific molecular cancer targets to combat 
drug resistance remains high.  One such molecule, survivin, has garnered substantial attention as 
a potential cancer specific target.  Survivin (also called BIRC5) is a member of the Inhibitor of 
Apoptosis Protein (IAP) family (Table 1) [2,3] and plays a critical role in both the inhibition of 
apoptosis and in cell cycle progression [4].  Survivin has been shown to be overexpressed in almost 
every type of cancer but is undetectable in most normal adult tissues [5].  Survivin’s aberrant 
expression, dual roles in cancer cell survival, and its correlation with resistance to chemotherapies 
and poor patient outcome make it a promising target for discovery of new cancer therapeutics.  The 
aim of this review is to discuss the distinct strategies that have been used to target survivin or its 
expression and the validity and potential of each as a relevant clinical cancer chemotherapeutic 
moving forward.  We will also provide future perspectives in targeting survivin for potential 
therapeutic discovery.   
Survivin structure and function 
 Survivin consists of 142 amino acid residues with a single zinc finger fold Baculovirus 
Repeat (BIR) domain, a dimerization domain at two different locations in the linear sequence, and 
a C-terminal domain for protein-protein interaction and nuclear export (see Figure 1A and 1B).  
Survivin exists as a stable bow-tie-shaped homo-dimer (Figure 1C) formed through interactions of 
the N-terminal region, linker region, and the N-terminus of alpha helix four [6].  The homo-dimeric 
interface is mostly hydrophobic with greater than 75% of the residues being nonpolar [7]. The 
buried accessible area in the interface of a monomeric survivin is 550 Å2 and occupies only 6% of 
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the total accessible area of a monomer (9,044 Å2) compared with ~20% in most other dimeric or 
oligomeric proteins [8]. 
 Ectopic over-expression of survivin inhibits both extrinsic and intrinsic apoptosis pathways 
in cell lines and animal models [9-12].  However, the exact mechanism in apoptosis inhibition by 
survivin remains unknown with the binding of survivin to caspases being proposed as a possible 
mechanism (Figure 2).  Survivin has been suggested to directly bind to and inhibit caspase 3 and 
7 while contradictory evidence exists that brings this observation under scrutiny [13,14]. Although 
myc-tagged survivin in HEK293 cells co-immunoprecipitated with active caspase 3 and 7, survivin 
seemingly lacks the additional structural moieties such as the BIR2 domain that have been 
demonstrated to be necessary for caspase 3 and 7 binding by other IAP family members [15-17]. 
It has also been suggested that survivin can bind to caspase 9 and inhibit its activation [18]. 
However, it was shown later using purified proteins that survivin alone does not bind to caspase 9 
and it may require the presence of hepatitis B X-interacting protein (HBIXP) to bind to and inhibit 
caspase 9 [19]. The interaction between survivin and HBIXP may be responsible for binding to 
pro-caspase 9 to prevent its recruitment to the apoptosome and, thus, inhibit its activation [19].  It 
has also been postulated that an IAP-IAP complex between survivin and X-linked IAP (XIAP) 
may form to stabilize XIAP and lead to inhibition of caspase 9 [20].  Finally, survivin may prevent 
the induction of apoptosis by interaction with intermediate apoptotic proteins to indirectly halt 
caspase activation.  SMAC/DIABLO is a proapoptotic protein that promotes cytochrome c 
dependent apoptosis by binding to and antagonizing IAPs [21].  Survivin can bind 
SMAC/DIABLO and prevent SMAC/DIABLO inhibition of caspases [22].  Survivin has been 
shown to co-localize with SMAC/DIABLO and disruption of their physical association induces 
apoptosis [23]. Thus, it is possible that survivin inhibits apoptosis via interaction with multiple 
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proteins in the apoptosis pathway. 
 In addition to the inhibition of apoptosis, survivin acts as a key mitotic regulator (Figure 2) 
and is essential for proper completion of mitosis and cell division [24].  Survivin expression is 
tightly regulated during the cell cycle progression, peaking in the G2/M phase [25].  During 
mitosis, survivin localizes and interacts with microtubules to regulate microtubule formation 
during cell division by altering microtubule dynamics and nucleation [26].  Additionally, survivin 
is a critical component of the chromosomal passenger complex (CPC) that also consists of 
INCENP, Borealis, and Aurora B Kinase [27].  INCENP acts as a scaffold to stabilize the entire 
complex, while Borealis promotes the attachment of survivin to the complex [28].  Survivin 
appears to function in targeting of the CPC to the centromere and midbody during mitosis.  The 
CPC is a critical regulator of several mitotic events [29] and, when localized to the midbody, it 
facilitates proper chromosome alignment during metaphase [30].  The CPC is also vital for 
correction of chromosome-microtubule attachment errors [31] and activation of the spindle 
assembly checkpoint [32].    
Survivin as a target for therapeutic discovery 
 For over a decade, survivin has drawn a considerable attention as a potential novel drug 
target in a variety of human cancers.  The attractiveness of survivin as a potential cancer drug 
target has been in large part due to its dramatic dysregulation of expression between normal adult 
tissues and most cancers.  Survivin is expressed to a high extent in fetal tissues [33], but is 
undetectable in most normal adult tissues [34].  Interestingly, survivin is overexpressed in almost 
all human cancers including cancers of lung, breast, colon, stomach, esophagus, pancreas, prostate, 
liver, and ovary [35].   
 Survivin has been consistently demonstrated to be an important contributor to both 
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radiotherapy [36] and chemotherapy resistance [37,38].  High level of survivin expression is 
predictive of poor clinical outcome  and correlates with relapse  in bladder cancer [39], non-small 
cell lung cancer [40], gall bladder carcinoma [41], locally advanced rectal cancer [42]. renal cell 
carcinoma [43], and breast cancer [44,45].   
 Expressing recombinant dominant negative survivin produced pro-apoptotic and anti-
proliferative effects on human cancer cells and suppressed tumor growth in vivo [46-48].  Cleavage 
of survivin mRNA by ribozyme increased cell death by caspase dependent apoptosis [49].  Down 
regulation of survivin expression by antisense oligonucleotides [50] and siRNAs inhibited cancer 
cell proliferation and increased chemosensitivity [51].  These studies using molecular probes along 
with the expression profile of survivin in cancer and its clinical relevance have clearly established 
survivin as a target for anticancer drug discovery.   
Therapeutics targeting survivin 
 Despite the promise and interest in survivin as a target for anticancer drug discovery, at 
present time there exists a small portfolio of anti-survivin agents, which can generally be classified 
in to three broad categories of inhibitors targeting (1) regulators of survivin expression, (2) survivin 
interaction with ligand proteins, and (3) survivin homo-dimerization.  In addition, survivin has 
also been considered and tested as a cancer vaccine for immunotherapy. 
1. Inhibitors targeting survivin expression. Because survivin has no known enzymatic 
activities and it is considered “undruggable”, the initial effort of targeting survivin was not on the 
survivin protein itself, but rather on inhibiting survivin expression to avoid targeting survivin 
protein directly. This approach includes the use of antisensense oligonucleotides and small-
molecule inhibitors.  
1.1. Antisense oligonucleotides. Antisense oligonucleotides such as LY2181308 and 
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SPC3042/EZN-3042 (Table 2) have been developed to inhibit survivin expression as anticancer 
therapeutics. These oligonucleotides have been tested in clinical studies with mixed findings. 
 LY2181308 is a 2’-O-methoxymethyl-modified single strand antisense oligonucleotide 
targeting survivin mRNA to limit survivin expression developed by Eli Lilly [52].  LY2181308 
inhibited the expression of survivin gene at both mRNA and protein levels in a panel of cell lines 
and it significantly inhibited growth of human tumor xenografts [52,53].  The positive pre-clinical 
activity of LY2181308 led to its clinical testing as a single agent and in combination with other 
chemotherapeutics.  However, the outcome of these clinical studies are mixed.  LY2181308 was 
well tolerated as a single agent and did not appear to cause additional toxicity to cytarabine and 
idarubicin in refractory or relapsed AML patients [54]. With this cohort of 16 AML patients, it 
appeared that the combination of LY218308 with cytarabine and idarubicin showed synergistic 
benefits. LY218308 also inhibited survivin expression in patients with high survivin level although 
the correlation between survivin inhibition and response was not studied.  It is also noteworthy 
that the cohort size in this study was small and a bigger cohort size is needed to validate the findings 
on the synergism.  
 The findings from clinical study of LY218308 on solid tumors are not encouraging. Neither 
the phase I trial of LY218308 as a single agent for solid tumors [55] or in combination with 
docetaxel/prednisone in a phase II trial for castration-resistant prostate cancers [56] showed any 
benefit of LY2181308.  The authors noted that lack of response might be due to the lack of survivin 
inhibition by LY2181308 in these solid tumors although survivin expression was not measured in 
these studies and they were unable to achieve the required pharmacokinetic levels necessary for 
survivin inhibition. 
 SPC3042 is a locked antisense oligonucleotide that targets the stop codon of the open reading 
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frame in exon 4 of the survivin transcript and was under preclinical development by Santaris 
Pharma [57].  SPC3042 displayed improved potency compared to LY2181308.  However, unlike 
LY2181308, SPC3042 had a significant effect also on the mRNA and protein levels of Bcl-2 in 
addition to that of survivin.  Down regulation of survivin expression by SPC3042 sensitized PC3 
prostate cancer xenograft to taxol treatment in vivo.  In 2006, Santaris Pharmaceuticals licensed 
the developmental rights of SPC3042 to Enzon-Pharmaceuticals and it was rebranded as EZN-
3042.  In primary ALL cells, EZN-3042 synergized with chemotherapy and eliminated ALL cells 
in vitro [58].  EZN-3042 also demonstrated success in vivo as it achieved ~60% down regulation 
of survivin mRNA in Calu-6 lung xenografts and ~40% tumor growth inhibition.  In combination 
with paclitaxel, EZN-3042 achieved >80% tumor growth inhibition [59].  However, the phase I 
trial of EZN-3042 was terminated since EZN-3042 produced several dose-limiting toxicities and 
it was unable to be safely administered with other chemotherapeutics [60].  As such, further clinical 
development of this oligonucleotide has been halted by Enzon Pharmaceuticals.    
 In summary, the success in clinical trials has been limited by targeting survivin expression 
using antisense oligonucleotides, particularly for solid tumors. The lack of response in solid tumors 
suggests that this strategy of inhibiting survivin expression may have limited potential in targeting 
survivin and treating the difficult-to-treat and aggressive solid tumors.  One contributing factor to 
the ineffectiveness of antisense oligonucleotides may be the intrinsic disadvantages of 
oligonucleotides including stability and availability issues. These disadvantages may also account 
for the dose limiting toxicities that have been evident in previous trials and are consistent with the 
currently limited portfolio of FDA-approved antisense oligonucleotide therapeutics.    
1.2. Small-molecule inhibitors. In addition to antisense oligonucleotides, small-molecule 
inhibitors (Table 3) have also been developed by targeting transcription of the survivin gene. These 
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inhibitors include YM155 and EM-1421, which have been tested in clinical studies, and other 
compounds such as SF002-96-1 and FL118, which are still at the pre-clinical stage. 
 YM155 (sepantronium bromide) is the first small-molecule inhibitor targeting the expression 
of survivin, identified via high throughput screening (HTS) using a survivin-promoter-luciferase 
reporter assay aiming to identify small-molecule inhibitors that may bind to the promoter sequence 
of the survivin gene [61]. YM155 potently inhibited survivin-promoter-driven luciferase 
expression without effect on the expression of other antiapoptotic proteins. It also effectively 
inhibited growth of human prostate PC3 ectopic xenograft tumors. In a follow-up study, YM155 
induced cell death with an average IC50 of 15 nM in a panel of 119 human cancer cell lines [62]. 
Continuous 3- or 7-day YM155 infusion in xenograft models also showed significant tumor-
suppressing activity on different tumors including melanoma and cancers of breast, lung, and 
bladder without significant toxicity as indicated by little body weight loss [62,63].   
 Due to the promise of YM155 in cell-based and preclinical studies, it has been investigated 
in clinical trials as a single agent and in combination with other anticancer therapies (for a review 
see [63]). While YM155 is well tolerated with a MTD of 4.8 mg/m2 [64] and it has shown some 
efficacy against blood cancers, mixed results were generated when tested against various solid 
tumors with modest efficacy at best for some tumors [63]. For example, no improvement in 
response rate was observed for non-small cell lung cancer patients in multiple phase II trials of 
YM155 as a single agent and in combination with carboplatin and paclitaxel [65,66] while a phase 
II trial of castration resistant prostate cancers (CRPC) showed modest activity with 25% of patients 
displaying prolonged stable disease [67]. While the mixed successes of YM155 in clinical studies 
suggest that targeting survivin may help identify a novel approach to cancer therapy, clinical 
development of YM155 is now questionable. One confounding factor is that YM155 cannot be 
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used for bolus dosing and has to be continuously infused 24 hrs a day in 3- or 7-day dosing cycles. 
Currently there are no ongoing clinical trials with YM155.   
 Since the discovery of YM155, there have been large undertakings to determine its precise 
mechanism of action.  While it has been shown to inhibit survivin transcription, it does not work 
via binding to survivin promoter sequence as anticipated but rather by inhibiting the survivin 
upstream transcription factor Sp1 [68].  Evidence also exist to suggest that YM155 may inhibit 
survivin expression by disrupting interleukin enhancer-binding protein factor 3 and p54nrb 
complex, a critical complex for transcription of survivin [69]. There is also compelling evidence 
to suggest that YM155 may be a DNA damage-inducing agent [70] and its inhibition of survivin 
expression may be secondary to this event.  Considering that Sp1, the target of YM155, is a 
ubiquitous transcription factor and that its inhibition of survivin expression may be a secondary 
event to DNA damages [70], YM155 unlikely inhibits survivin expression specifically. Hence, 
designating YM155 as a survivin inhibitor is inappropriate and misleading.   
 EM-1421 (terameprocol) is another small-molecule transcriptional repressor of the survivin 
gene under development as survivin inhibitor by Erimos Pharmaceuticals that acts to inhibit the 
ubiquitous transcription factor Sp1 [71].  In addition to inhibiting survivin expression, EM-1421 
has been shown to also inhibit the expression of cdc2, another Sp1-controlled gene [72].  EM-1421  
induced G2 cell cycle arrest in a variety of solid tumor cell lines [73] and systemic treatment with 
EM-1421 suppressed the growth of human tumor xenografts including breast, prostate, colorectal, 
and liver cancers [74].  Using clonogenic survival assays, it was found that EM-1421 was able to 
induce radiosensitization in non-small cell lung cancer cells [75].  Similar as YM155, EM-1421 
has been tested in clinical trials. For advanced leukemia patients, EM-1421 demonstrated a safe 
profile and showed partial responses in a few patients with CML or AML in a phase I study [65,76].  
12  
However, in a phase I study for high grade gliomas, EM-1421 did not display any response and 
stable disease was observed in 32% of patients [77].  Most recently, the safety profile of EM-1421 
was tested as a vaginal ointment for treatment of cervical intraepithelial neoplasia caused by human 
papilloma virus [78] in a Phase I/II trial using healthy adult women.  The ointment with 1% and 
2% EM-1421 showed a promising safety profile with no severe adverse effects in healthy subjects.   
 SF002-96-1 is a natural drimane sesquiterpene lactone isolated from Aspergillus that was 
identified to potentially inhibit survivin promoter activity using survivin-promoter-driven reporter 
assay in Colo320 cells [79], similarly as described above for identification of YM155. SF002-96-
1 decreased Colo320 cell viability and induced apoptosis as evidenced by increased caspase 3 
activity and cleaved chromosomal DNA by DAPI staining.  Further studies using promoter-
reporter assay, SF002-96-1 was shown to inhibit the activity of transcription factors STAT3 and 
NF-κB but not TCF/β-catenin, which all regulates survivin transcription, and also decreased 
survivin mRNA and protein levels. Thus, SF002-96-1 may inhibit survivin expression by 
inhibiting multiple upstream transcription factors such as STAT3 and NF-κB. As with other 
nonspecific strategies, unexpected dose-limiting toxicities may result from the disruption of other 
genes besides survivin, which may limit the utility of SF002-96-1 going forward.   
 FL118 is a nonselective small-molecule inhibitor of survivin expression that structurally 
resembles the topoisomerase I inhibitor, irinotecan.  FL118 appears to inhibit survivin expression 
by disrupting survivin promoter activity. However, FL118 also down regulates the expression of 
Mcl-1, XIAP, and cIAP2.  Strikingly, FL118 displayed greater anti-tumor activity in squamous 
cell carcinoma and colon cancer cell line-derived xenografts, as well as a patient-derived head and 
neck cancer xenograft as compared to leading first line chemotherapeutics [80].  A detailed 
molecular mechanism of FL118 action is currently lacking but warranted with the promising in-
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vivo data.   However, based on the studies of YM155, it is tempting to speculate that FL118 may 
also inhibit upstream transcription factors that regulate survivin expression. It may also be possible 
that the effect of FL118 on survivin expression is a secondary effect of DNA damage potentially 
induced by FL118 inhibition of topoisomerase (see discussion above on YM155).  
 GDP366 is a small-molecule compound that has been found to reduce the mRNA and protein 
levels of both survivin and oncoprotein Op18.  Treatment with GDP366 inhibits cancer cell 
proliferation both in vitro and in vivo [81].  Little data are available to evaluate GDP366 and more 
mechanistic studies are needed to elucidate the mechanism of action by which GDP366 produces 
its effects on survivin expression and its potential as a cancer therapeutics.   
  While targeting the transcription of survivin gene has gained progresses with YM155 and 
EM-1421 tested in clinical trials, the common issues with all these inhibitors are that they are not 
selectively targeting survivin expression. Most of these inhibitors act on one or more upstream 
transcription factors that regulate the expression of survivin as well as many other downstream 
genes.  Effectively, these inhibitors are not survivin inhibitors but rather transcription factor 
inhibitors. The lack of specificity of these inhibitors in targeting survivin transcription as identified 
using survivin promoter activity assay and designating these compounds as survivin inhibitors are 
indeed troubling.  
 Although both YM155 and EM-1421 have generally been tolerated in clinical trials despite 
the fact that they both inhibit a ubiquitous transcription factor Sp1, their limited clinical efficacies 
suggest that targeting the survivin upstream transcription factors such as Sp1 to limit survivin 
expression may unlikely represent an appropriate strategy to target survivin for therapeutic 
development. It is also unclear if the other downstream target genes of these transcription factors 
may work against the inhibition of survivin expression in suppressing cancers in the clinical 
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setting. These findings also indicate that targeting Sp1 may not lead to effective cancer therapeutics 
for development.  
2. Inhibitors targeting survivin interaction with other proteins. Because survivin is 
known to work by binding to and interacting with many important cellular proteins, there have 
been various efforts in targeting survivin interaction with its binding partners (see Table 4). 
 The first in this category of inhibitors is called shepherdin, a peptide with a sequence (K79H 
SPGCAFL87) of survivin that inhibits Hsp90 interaction with survivin and destabilizes survivin 
[82]. Tagging the amino terminus of sheperdin to either helix III of the Antennapedia or HIV-/Tat 
sequence led to a cell permeable shepherdin that was able to accumulate in cells and inhibit 
survival of HeLa, PC3, and DU145 cells by inducing apoptosis without apparent effect on normal 
cells. The cell permeable shepherdin also effectively inhibited PC3 xenograft growth in vivo. 
Because shepherdin binds to Hsp90 and may destabilize many proteins including survivin, the cell 
death induced by shepherdin could be due to multiple factors regulated by Hsp90. It would be of 
interest to determine if a peptide with a sequence from Hsp90 that inhibits Hsp90 binding to 
survivin has similar effects as shepherdin. 
 In another study searching for peptide mimetics interacting with survivin using yeast two-
hybrid system, a peptide derived from heavy chain 1 of ferritin was identified to interact with 
survivin [83]. Interestingly, this peptide, when cloned into a disabled thioredoxin for purification 
of recombinant protein, was able to bind to survivin and suppress survivin expression and induce 
apoptosis in breast and glioma cancer cells. The reduced survivin expression appears to be 
proteasome dependent. However, these authors have also shown that the full-length heavy chain 1 
of ferritin does not interact with survivin. Thus, the peptide-induced survivin loss may not be via 
inhibition of survivin interaction with ferritin.  It remains to be determined how this peptide derived 
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from ferritin would induce loss of survivin and induce apoptosis of cancer cells.   
 Using a shape-based structural screening for the second mitochondria-derived activator of 
caspase (SMAC) mimetic that would inhibit interaction between SMAC and IAP proteins, a novel 
hit compound, UC-112, was identified that significantly activate caspases in melanoma and 
prostate cancer cell lines [84].  Continuous treatment of A375 melanoma xenograft tumors with 
UC-112 for 3 weeks significantly inhibited tumor growth in a dose-dependent manner with little 
reduction in the body weight of the mice.  Interestingly, UC-112 dose-dependently inhibited 
survivin expression as well as expression of other IAPs albeit to a less extent. Currently, it is 
unknown if UC-112 disrupts the interaction between SMAC and survivin or other IAPs. It is also 
unknown how UC-112 suppresses the expression of survivin and other IAPs. However, it appears 
that UC-112 may reduce their stability via proteasome-dependent manners. Computational 
docking analysis predicts that UC-112 may bind to the BIR domain of survivin [85] although 
experimental evidence is needed to prove this binding. It also remains to be determined why 
disrupting the interaction between SMAC and IAPs by UC-112 would lead to degradation of IAPs. 
Does UC-112 have other unknown activities that would facilitate the degradation of survivin and 
other IAPs, perhaps by changing the conformation of these proteins? Many questions remain to be 
answered in order to further develop UC-112 as a SMAC mimetics to inhibit survivin and/or other 
IAPs. 
 In a follow-up structure-activity relationship study, analogs of UC-112 were synthesized and 
analyzed [85].  One of the analogs, 4g, has an iso-propyl group substituted on the C-linker of UC-
112 (Table 4) with a 4-fold increase in activity in growth inhibition of cancer cell lines and 
increased selectivity to survivin as compared to UC-112.  4g also proved effective in inhibiting the 
A375 melanoma xenograft in vivo similar as the parent compound UC-112.  The successes of 
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these studies certainly warrant further mechanistic investigation of SMAC mimetics as survivin 
inhibitor and for potential development. SMAC mimetics represent an approach that inhibit 
survivin interaction with other proteins by binding to survivin and, thus, eliminate other effects by 
binding to its partners as in the case of shepherdin. However, modification and optimization of 
SMAC mimetics are likely needed to increase its specificity to survivin over other IAPs, which 
may prove to be difficult since their binding site, the BIR domain, is the consensus signature 
domain of IAPs.  
 Withanone is a herbal ligand from the plant Withania somnifera, which was predicted to bind 
to the BIR domain of human survivin using computational docking analysis and to interfere with 
the caspase inhibitory function of survivin [86] similar as UC-112.  However, no experimental 
testing has been conducted on withanone to determine if it inhibits or binds to survivin although 
withanone has been shown previously to have mild activity in inhibiting proliferation of various 
cancer cell lines [87-89].  Clearly, more studies are need to investigate if this natural product hold 
any promise in binding to survivin and inhibiting its interaction with SMAC.   
 In another study, the protein-protein interaction sites in survivin were analyzed in-silico and 
hotspot residues were identified and used to generate a potential pharmacophore that may interfere 
survivin interaction with its binding partner chromosome passenger complex (CPC) [90]. HIV 
protease inhibitors, particularly Indinavir, was found to match the pharmacophore. Although 
Indinavir was able to inhibit the survival of MDA-MB-231 breast cancer cells with an IC50  greater 
than 500 µM, it is unknown if Indinavir binds to survivin and inhibits its interaction with its 
binding partners such as those involved in the formation of the CPC. Interestingly, Indinavir 
decreased the XIAP protein level and increased caspase 3 cleavage. It remains to be determined if 
this effect was via binding to and inhibiting survivin. It is noteworthy that another HIV protease 
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inhibitor, Nelfinavir, has previously been shown to be able to potentiate Imatinib cytotoxicity in 
meningioma and inhibited survivin expression [91] while Indinavir did not affect survivin 
expression. Thus, it is unclear if these HIV protease inhibitors actually bind to and inhibit survivin 
interaction with its ligand proteins. Clearly, more studies remain to be conducted on these HIV 
protease inhibitors to determine if they bind to or act on survivin and can be repurposed as potential 
new anti-cancer therapeutics by binding to and inhibiting survivin. However, because of its high 
IC50 at 500 µM, Indinavir will unlikely be repurposed as a survivin-targeting anticancer drug. 
 Due to lack of known enzymatic activities and, thus, lack of high throughput assays for 
survivin, Abbot Laboratories conducted an NMR- and affinity-based screening of their libraries 
for compounds binding to survivin and identified Abbot 8 that binds to a pocket in survivin, with 
a Kd of 75 µM, that may affect protein-protein interaction [92].  Via structure-activity analysis, 
modification of Abbot 8 increased its affinity in binding to survivin. However, Abbot 8 and its 
analogs were not tested for their activity in suppressing cancer cells or in inhibiting survivin 
interaction with its binding partners in this initial report.  
 Using Abbot 8 as a lead compound targeting a site that may affect protein-protein interaction, 
three compounds (LLP3, LLP6, and LLP9) were synthesized and tested as survivin modulators 
[93].  While LLP6 has no effect on cancer cells, LLP3 and LLP9 were able to delay mitosis and 
inhibit proliferation of HUVEC and PC3 cells. When tested against two isogenic glioma cell lines, 
LLP3 has an IC50 of 13.6-38.1 µM [94]. LLP3 was shown to be able to disrupt the interaction 
between survivin and its binding partner Ran [94], which may be responsible for the anticancer 
activity of LLP3.  Thus, Abbot 8 and the LLP derivatives may work by inhibiting survivin 
interaction with its binding partners. Additional studies are clearly needed to investigate the fate 
of survivin following the binding of LLP compounds and survivin release from its binding partners 
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in the CPC. 
 Similar to LLP3, S12 was identified as a survivin-targeting molecule capable of binding to 
a cavity in survivin that may induce conformational changes in the protein structure that disrupt 
normal functions of survivin [95].  S12 treatment alters microtubule dynamics in cancer cells, 
resulting in disruption of spindle formation, misalignment of chromosomes during metaphase, and 
G2/M cell cycle arrest.  S12 also inhibits cancer cell proliferation in vitro and suppresses growth 
of pancreatic xenograft tumors in a dose dependent manner without effecting the overall 
expression of survivin.  In an additional study, S12 also inhibited the proliferation and growth of 
sonic hedgehog driven medulloblastoma cancer cells by inducing cell cycle arrest and apoptosis 
[96].  The detailed mechanism of action of S12 and whether it affects survivin interaction with its 
binding partners is awaiting to be investigated. 
 In summary, it is clear from the above discussions that the strategy targeting survivin 
interaction with its binding partners helps circumvent the issues encountered in targeting upstream 
regulators of survivin expression. This strategy may result in true survivin inhibitors that bind 
directly to survivin protein. However, limitations also exist with this approach. Firstly, inhibitors 
such as shepherdin does not bind to and inhibit survivin. Instead, it binds to and inhibits survivin’s 
binding partner Hsp90, which also regulates the stability of other proteins in addition to survivin. 
Thus, inhibitors such as shepherdin are not specific to survivin and may represent Hsp90 inhibitors. 
Secondly, inhibitors such as UC-112 bind to the BIR domain, which is a consensus signature 
domain of IAPs. Thus, it may prove to be challenging to generate a true survivin-selective inhibitor 
that does not affect other IAPs. Thirdly, it is currently unknown what other or all protein partners 
of survivin would be affected by the inhibitors such as LLP3 designed to inhibit survivin 
interaction with other protein partners.  Finally, the data on the mechanism of action of this 
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category of inhibitors, especially LLP compounds and S12, are limited for detailed evaluation. 
More studies are needed to determine the value of the strategy in targeting survivin interaction 
with its binding partners. 
3. Inhibitors targeting survivin homo-dimerization. Because survivin has no known 
enzymatic activities but works as a homo-dimer, targeting its homo-dimerization for identifying 
and developing survivin inhibitors has recently been attempted [8]. This approach not only helps 
circumvent some of the issues encountered in targeting upstream regulators of survivin expression 
and result in true survivin inhibitors that bind directly to survivin proteins, it may also help 
eliminate survivin protein, resulting in spontaneous apoptosis due to survivin elimination. Because 
the homo-dimerization interface of survivin is unique, the inhibitor to this site is likely to be 
selective to survivin over other IAPs. 
 As discussed above, the buried accessible area in the homo-dimeric interface of a monomeric 
survivin is 550 Å2 and occupies only 6% of the total accessible area of a monomer (9,044 Å2) 
compared with ~20% in most other dimeric or oligomeric proteins [8]. Thus, targeting the homo-
dimerization interface to disrupt survivin homo-dimerization would be feasible. Furthermore, 
disrupting survivin homo-dimerization will lead to exposure of the hydrophobic dimeric interface, 
which would target the protein to proteasome for degradation. In a recent in-silico screening study 
targeting the critical dimerization residues following detailed computational analysis of the 
dimerization interface, a hit molecule, LQZ-7, was identified [8] (see Table 5).  LQZ-7 not only 
was able to specifically disrupt survivin dimerization and inhibit cancer cell survival, it was also 
able to induce survivin degradation in a proteasome-dependent manner. However, it had no effect 
on survivin transcription or synthesis nor the expression of other members of the IAP family 
(unpublished observations). 
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 Further analysis of LQZ-7 analogs led to identification of superior compounds including 
LQZ-7F that can more effectively disrupt survivin dimerization, cause proteasome-dependent 
survivin degradation, and inhibit cancer cell survival.  The IC50 of LQZ-7F against a panel of 
human cancer cell lines ranged from 0.4-4.4 µM and it induced spontaneous apoptosis in these 
cancer cells.  Using pull-down assay with immobilized LQZ-7F and purified survivin, it was found 
that LQZ-7 can directly bind to survivin, possibly to the interface for homo-dimerization (Figure 
3). LQZ-7F also showed promising in-vivo activity. It effectively inhibited the growth of PC3 
xenograft tumors and reduced survivin protein in the xenograft tumors as expected. LQZ-7F was 
also well tolerated without affecting the body weight of the mice [8].  Future studies of LQZ-7F 
and other LQZ-7 analogs as well as further optimization may prove fruitful in targeting survivin 
homo-dimerization for developing novel true survivin-targeting cancer drugs.  
Docking LQZ-7 and LQZ-7F in survivin revealed how they interact with the dimerization 
residues (Figure 3A and 3B). LQZ-7 has three important interactions with survivin via (a) H-bond 
between an aniline NH group of LQZ-7 and Glu94 of survivin; (b) interaction between the 
substituted aniline in LQZ-7 and Phe93, Phe101, and Leu98 in the hydrophobic pocket of survivin 
via π-π stacking and hydrophobic interaction; and (c) H-bond between the carboxylic acid of LQZ-
7 and Trp10 of survivin. LQZ-7F has two key interactions with survivin via (a) H-bond between 
the primary amine group of LQZ-7F and Glu94 of survivin and (b) the tetracyclic furazanopyrazine 
ring of LQZ-7F interacts with Phe101, Phe93, Leu98, and Trp10 via π-π stacking and hydrophobic 
interactions. These interactions may effectively inhibit survivin homo-dimerization. 
 Based on the above pre-clinical studies, targeting survivin by disrupting its homo-
dimerization may be a good strategy going forward.  Although it has been shown that LQZ-7 and 
LQZ-7F bind to survivin, disrupt survivin homo-dimerization, and induce survivin degradation, it 
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is yet unknown if they truly bind to the homo-dimerization interface of survivin as intended. Since 
this study is the only one that has shown targeting the homo-dimerization domain of survivin, 
caution needs to be taken when considering targeting survivin by disrupting its homo-dimerization. 
Additional independent studies are clearly needed to demonstrate the feasibility of this strategy in 
targeting survivin and possibly other homo-dimeric proteins for therapeutic discovery. It is also 
noteworthy that targeting homo-dimerization is more challenging than targeting survivin 
interaction with other proteins. It will be very perplexing to establish a high throughput assay to 
investigate and target homo-dimerization. In-silico screening may have to be used for such studies 
as demonstrated by the study discussed above. 
 4. Survivin vaccine and immunotherapy. The fact that survivin is over-expressed in 
many cancers but not expressed in most adult normal tissues has led many to believe that it may 
have potential to serve as a cancer vaccine for immunotherapy.  Although this concept is relatively 
new, there have been therapeutics fast tracked to clinical trials (Table 6).   
 In one study, it was found that an 8-amino acid peptide survivin-2B80-88 
(A80YACNTSTL88), derived from survivin 2B, a splicing variant of survivin, binds to HLA-A24 
and is recognized by CD8+ cytotoxic T lymphocytes [97]. Cytotoxic T lymphocytes induced by 
survivin-2B80–88 ex vivo are capable of recognizing and acting on cancer cells expressing HLA-
A24 and presenting endogenously processed survivin-2B peptide in tumor cells. Also, HLA-A24-
restricted cytotoxic T lymphocytes from peripheral blood mononuclear cells of HLA-A24+ breast, 
colorectal, and gastric cancer patients can be induced by the survivin-2B80–88 peptide and they 
effectively cause cytotoxicity against HLA-A24+ but not HLA-A24- lung adenoma A549 cell line 
[98].  These data formed the basis for a phase I clinical trial using the survivin-2B80–88 peptide 
in patients with advanced or recurrent breast and colorectal cancers [99,100].  Although survivin-
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2B80-88 was well tolerated, it unfortunately did not elicit significant clinical response alone or in 
combination with incomplete Fruend’s adjuvant in these patients.  
 In a similar study, another survivin peptide mimetic SVN53-67/M57-KLH or SurVaxM that 
can be presented by MHC class I to induce CD8+ cytotoxic T lymphocytes [101]. Immunization 
of C57BL/6 mice with this peptide resulted in rejection of orthotopic GL261 glioma xenografts. 
SVN53-67/M57 also stimulated cytotoxic T lymphocyte responses against human tumor cells of 
several different MHC class I haplotypes ex vivo. Currently, two ongoing clinical trials for newly 
diagnosed glioblastomas and multiple myelomas are actively recruiting participants to test the 
efficacy of SVN53-67/M57 (https://clinicaltrials.gov).   
 Cancer immunotherapies targeting survivin certainly offer an exciting approach for treating 
cancers.  The ability to direct the immune system to recognize and kill cancer cells is 
revolutionizing cancer treatment. While survivin peptides and mimetics have yet to demonstrate 
significant clinical efficacy in immunotherapy, it is promising that they appear to be well tolerated 
and do not produce apparent toxicities. Also, it may not induce aberrant immune reactions as some 
other immunotherapeutics. Clearly, this approach is exciting as it may be a way to produce a robust 
immune response specifically against cancer cells that overexpress survivin.   
Conclusion and Perspectives 
 Survivin has consistently been demonstrated to be a critical factor in tumor progression and 
resistance to chemotherapy.  The fact that survivin is overexpressed in almost every cancer but not 
expressed in most adult normal tissues has positioned it as a strong tumor marker with a robust 
correlation to poor patient prognosis. Despite the limited response of currently available 
therapeutics targeting survivin in clinical trials, targeting survivin for cancer intervention remains 
a highly attractive option.  The lack of efficacy and dose-limiting toxicities in clinical trials despite 
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strong pre-clinical data for some inhibitors may be attributable to a deficiency in true survivin-
specific inhibition.  Strategies that target survivin directly by methods such as immunotherapy or 
direct homo-dimerization inhibitors may hold the key to overcome some of the inadequacies of 
previous attempts in targeting survivin moving forward.  Considering the fact that inhibiting 
survivin enhances the apoptotic response of tumor cells induced by chemo or radiotherapies, there 
remains an opportunity to be exploited for combinational therapy including direct survivin 
inhibitors and current standard of care treatments. This combinational approach may shed light on 
potential synergistic effects and may overcome the drug or radiation resistance paradigm in many 
cancers.  
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Figure Legends 
Figure 1. Structure of survivin.  A. Schematic linear structure of survivin with domains 
highlighted in different colors. DD, dimerization domain; BIR, Baculovirus Repeat domain; PBD, 
protein-binding domain; NE, nuclear export. B. Atomic structure of survivin (PDB 1F3H) with 
domains color in correspondence with that shown in the linear structure in panel A. The zinc finger 
residues (Cys57, Cys60, His77, and Cys84) are shown in ball and stick symbols with the zinc ion 
shown as a red ball. C. Atomic structure of dimeric survivin (PDB 1F3H) with one subunit shown 
in pink and the other in blue.   
Figure 2. Participation of survivin in regulating apoptosis and cell cycle progression. 
Survivin regulates both cell cycle progression by binding to chromosomal passenger complex in 
the nucleus and apoptosis by binding to SMAC/DIABLO and caspases in cytoplasm. 
Figure 3. Predicted binding modes of LQZ-7 and LQZ-7F in survivin. Both LQZ-7 
(A) and LQZ-7F (B) interact with important residues for survivin homo-dimerization including 
residues Leu98 and Phe101. 
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Table 1. Members of the IAP family 
IAP Member Abbreviation Mol. Wt. Reference 
Neuronal apoptosis inhibitory protein NAIP/BIRC1 160 kDa      [102] 
Cellular Inhibitor of Apoptosis protein 1 c-IAP1/BIRC2 69 kDa      [103] 
Cellular Inhibitor of Apoptosis protein 2 c-IAP2/BIRC3 68 kDa      [103] 
X-linked Inhibitor of Apoptosis protein XIAP/BIRC4 55 kDa      [104] 
Survivin Survivin/BIRC5 16.5 kDa      [105] 
BIR repeat-containing ubiquitin conjugating 
enzyme 
BRUCE/BIRC6 528 kDa      [106] 
Melanoma IAP/Livin ML-IAP/livin/BIRC7 33 kDa      [107] 
IAP-like protein 2 ILP2/BIRC8 27 kDa      [108]    
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Table 2. Antisense oligonucleotides suppressing survivin expression 
Name Sequence Remark Reference 
LY2181308 5'-TGTGCTATTCTGTGAATT-3' In-vitro IC50 of 10-100 nM in 
inhibiting survivin expression. 
Lack of efficacy in phase II trials as 
a single agent or in combination 
with docetaxel 
[52-56] 
EZN-3042 5'-CTCAatccatggCAGc-3' In-vitro IC50 of 5 nM in inhibiting 
survivin expression and IC50 of 5-
40 µM in cell killing. 
Phase I trial terminated due to dose-
limiting toxicities 
[58-60] 
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Table 3. Small-molecule inhibitors suppressing survivin expression 
Name Structure Remark Reference 
YM155  Inhibitor of Sp1. 
In-vitro IC50 of ~15 nM.   
Phase I and II trials with 
modest efficacy.  
 
[61,62] 
EM-1421 
 
Inhibitor of Sp1. 
In-vitro IC50 of 5-40 µM. 
Phase I and II trials with 
partial response.  
[71-75]   
SF002-96-1  Inhibitor of STAT3 and NF-
κB  
In-vitro IC50 of 3.4 µM in 
inhibiting survivin promoter 
activity.  
[79] 
FL118  In-vitro IC50 of 6-8 nM 
In-vivo xenograft models of 
colon and head and neck 
cancers  
[80] 
GDP366  In-vitro IC50 of 1 µM (colon 
cancer cell line) 
In-vivo xenograft model of 
colon cancer 
[81] 
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Table 4. Inhibitors targeting survivin interaction with its ligand proteins 
Name Structure Remark Reference 
Shepherdin 
 
In-vitro IC50 of 25-75 
µM. 
In-vivo xenograft model 
of prostate cancer line 
[82] 
UC-112  In-vitro IC50 of 2.1 (0.7-
3.4) µM. 
In-vivo xenograft 
models of melanoma 
 
[84] 
 
4g  In-vitro IC50 of 0.5 µM. 
In-vivo model of 
melanoma cell line 
[84,85] 
Withanone  In-silico prediction only. 
No experimental data 
[86-89] 
Indinavir  In-vitro IC50 of >500 
µM (MDA-MB-231) 
[90] 
Nelfinavir  Inhibits survivin 
expression. 
In-vivo xenograft of 
meningioma.  
[91] 
Abbot 8  In-vitro Kd of 75 µM [92] 
LLP3  In-vitro IC50 of 13.6-
38.1 µM. 
In-vivo xenograft model 
of glioblastoma 
multiforme 
[93,94] 
S12  In-vitro IC50 of 6-8 nM 
(colorectal cancer cells) 
In-vivo xenograft 
models of pancreatic and 
medulloblastoma 
[95,96] 
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Table 5. Inhibitors targeting homo-dimerization of survivin 
Name Structure Remark Reference 
LQZ-7  In-vitro IC50 of ~20 µM for 
prostate cancer cell lines 
[8] 
LQZ-7F 
 
 
In-vitro IC50 of 2.4 (0.4-
4.4) µM for multiple cancer 
cell lines 
In-vivo xenograft model of 
prostate cancer 
[8] 
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Table 6. Immunotherapies targeting survivin 
 
Names Sequence Remark Reference 
Sur-2B80-88 AYACNTSTL Lack of clinical response in 
phase I trial 
[97-100] 
SurVaxM DLAQCFFMFKELEGW In-vivo glioma xenograft 
model. 
Clinical trials ongoing 
[101] 
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